SynAct Pharma AB SYNACT
OMXSTO · Sweden · Health Technology
SEK 17.18-0.32 (-1.83%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
LUND, SE / ACCESS Newswire / September 22, 2026 / AB (publ) ("SynAct") (STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as "pro-resolution", today announced its attendance and presentations at multiple upcoming conferences in September and October 2026.comInvestors and Media Mary-Ann Chang, Cohesion Bureau E-mail: synactpharma@cohesionbureau.
LUND, SE / ACCESS Newswire / September 16, 2026 / AB (publ) ("SynAct") (STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as "pro-resolution", today announced that the World Health Organization (WHO) has identified resomelagon, the company's once daily oral pro-resolution therapy, as one of six dengue therapeutic candidates with evidence supporting further clinical development.In a review to guide and accelerate clinic
LUND, SE / ACCESS Newswire / September 7, 2026 / AB (publ) ("SynAct")(STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as "pro-resolution", today announced results from a post-hoc analysis of the Phase 2b ADVANCE study evaluating resomelagon in treatment-naïve patients with highly active rheumatoid arthritis ("RA"). The analysis reinforces the positive results from the earlier Phase 2b EXPAND study and provides furthe
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.